Physician profile
Berrin Monteleone
NPI 1972765220
$50,228.06
in general payments reported to CMS, 2019-2025
13 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Clinical Genetics (M.D.) provider received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,675 · 2020: $6,087 · 2021: $19K · 2022: $6,673 · 2023: $11K · 2024: $1,378 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,400.00 |
| Food and Beverage | $1,193.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ptc Therapeutics, INC. | $33,203.81 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $7,409.98 | 2021-2024 | Strensiq |
| Acadia Pharmaceuticals INC | $4,168.21 | 2023-2025 | Daybue |
| Takeda Pharmaceuticals U.S.A., INC. | $2,450.05 | 2022-2025 | Elaprase, Vpriv |
| Akcea Therapeutics, INC. | $1,766.88 | 2019-2021 | |
| Genzyme Corporation | $485.64 | 2019-2025 | |
| Chiesi USA, INC. | $226.82 | 2024-2025 | Elfabrio |
| Alnylam Pharmaceuticals INC. | $179.52 | 2023-2025 | Amvuttra |
| Sobi, INC | $150.00 | 2023 | |
| Biogen, INC. | $124.68 | 2020 | |
| Amryt Pharma Holdings LTD | $25.67 | 2023 | Myalept |
| Travere Therapeutics, INC. | $20.48 | 2019-2023 | Cholbam |
| Genentech USA, INC. | $16.32 | 2023 | Evrysdi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Berrin Monteleone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.